Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Adaptive Randomized, Placebo -Controlled Trial of agenT-797 + Standard of Care Vs. Placebo + Standard of Care in Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure (AHRF) By Global ARDS Criteria

NCT07615010 is registered in ClinicalTrials.gov with MiNK Therapeutics as lead sponsor.

NCT NCT07615010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07615010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Adaptive Randomized, Placebo -Controlled Trial of agenT-797 + Standard of Care Vs. Placebo + Standard of Care in Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure (AHRF) By Global ARDS Criteria
Lead sponsor
MiNK Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
May 26, 2026
Completion date
August 31, 2027
Enrollment
90 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pneumonia